crmd_8k.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 13, 2014

CORMEDIX INC.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
 
001-34673
 
20-5894890
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
745 Rt. 202-206, Suite 303, Bridgewater, NJ
 
08807
(Address of Principal Executive Offices)
 
(Zip Code)

Registrant’s Telephone Number, Including Area Code: (908) 517-9500

 
(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
 
 
 
 
Item 8.01.   Other Events.

On January 13, 2014, CorMedix issued a press release announcing the establishment of letters of intent for the importation, sales, marketing and distribution of the Neutrolin® catheter lock solution with two leading Middle East distributors, as well as the establishment of a Sales and Marketing Oversight Committee of our Board of Directors.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01.   Financial Statements and Exhibits.

(d) Exhibits
 
 Exhibit No.      Description
     
 99.1    Press release dated January 13, 2014.
 
 
2

 
                      
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  CORMEDIX INC.  
       
Date: January 13, 2014   
By:
/s/ Randy Milby  
   
Name:  Randy Milby
 
   
Title:    Chief Executive Officer
 
       
 
 
3